We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+7.82%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$968M
AUM Growth
-$1.1B
(-53%)
Cap. Flow
-$1.16B
Cap. Flow
% of AUM
-120.21%
Top 10 Holdings %
Top 10 Hldgs %
41.41%
Holding
89
New
8
Increased
13
Reduced
37
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$40.1M |
| 2 |
ABMD
Abiomed Inc
ABMD
|
+$24.4M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$19.9M |
| 4 |
ADPT
Adeptus Health Inc
ADPT
|
+$10.4M |
| 5 |
Teladoc Health
TDOC
|
+$5.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$112M |
| 2 |
Amgen
AMGN
|
+$102M |
| 3 |
Gilead Sciences
GILD
|
+$102M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$84.5M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$83.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Thermo Fisher Scientific
TMO
$198B
| – | – |
-370,376
| Closed | -$52.4M |
|
77
Tandem Diabetes Care
TNDM
$1.17B
| – | – |
-26,869
| Closed | -$2.34M |
|
|
TVRD
78
Tvardi Therapeutics
TVRD
$30M
| – | – |
-33,683
| Closed | -$7.54M |
|
|
PRAH
79
DELISTED
PRA Health Sciences, Inc.
PRAH
| – | – |
-97,800
| Closed | -$4.18M |
|
|
AIMT
80
DELISTED
Aimmune Therapeutics
AIMT
| – | – |
-982,133
| Closed | -$13.3M |
|
|
MNK
81
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| – | – |
-27,467
| Closed | -$1.68M |
|
|
AKRX
82
DELISTED
Akorn Inc
AKRX
| – | – |
-33,744
| Closed | -$794K |
|
|
AGN
83
DELISTED
Allergan plc
AGN
| – | – |
-10,631
| Closed | -$2.85M |
|
|
TSRO
84
DELISTED
TESARO, Inc.
TSRO
| – | – |
-689,869
| Closed | -$30.4M |
|
|
STJ
85
DELISTED
St Jude Medical
STJ
| – | – |
-334,584
| Closed | -$18.4M |
|
|
IMDZ
86
DELISTED
Immune Design Corp.
IMDZ
| – | – |
-856,867
| Closed | -$11.1M |
|
|
ANAC
87
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| – | – |
-46,500
| Closed | -$2.48M |
|
Similar funds
RIP
CCM
LFWA
FWA
CF
WIM
MW
AFC
Sectoral Asset Management's Q2 2016 Portfolio in Review
As of Q2 2016, Sectoral Asset Management held 89 positions worth $968M, down 53% from $2.07B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Sectoral Asset Management withdrew a net $1.16B in Q2 2016, closing 25 positions and reducing 37 holdings. Its most notable exit was Amgen, an estimated $102M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier.
Against the trend, Sectoral Asset Management opened a new position in Pfizer worth $42M.
- Sectoral Asset Management's largest Q2 2016 buy was Pfizer: 1,256,716 shares worth $42M.
- Sectoral Asset Management added most to Abiomed Inc in Q2 2016, an estimated $24.4M increase.
- Sectoral Asset Management's biggest Q2 2016 reduction was Celgene Corp, cutting an estimated $112M.
- Sectoral Asset Management fully exited Amgen in Q2 2016, selling an estimated $102M.
- Sectoral Asset Management's ten largest holdings make up 41% of its $968M portfolio in Q2 2016.
- Sectoral Asset Management opened 8 new positions and closed 25 in Q2 2016.
- Sectoral Asset Management's portfolio value fell 53% quarter-over-quarter to $968M.
Based on Sectoral Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.